This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online version of the article only. Distribution for non-commercial purposes only. 
Introduction
Heme oxygenase-1 (HO-1) is a microsomal enzyme that catalyzes the rate-limiting step in the degradation of heme resulting in equal-molar quantities of carbon monoxide (CO), iron ions and biliverdin. Biliverdin can be further converted by biliverdin reductase to bilirubin, which possesses antioxidant activity. It is well-accepted that HO-1 is a cytoprotective enzyme and the enzymatic activity of HO-1 results in decreased oxidative stress, attenuated inflammatory response, and a lower rate of apoptosis [1] . However, in cancer cells, HO-1 expression is generally higher than that in normal cells which often leads to resistance to chemotherapy [2] . For this reason, HO-1 is currently considered a cancer therapeutic target [3, 4] .
Zinc is an essential trace element in plants and animals functioning in structural, enzymatic catalyst, and regulatory activities in these cells [5] . Zinc deficiency has been identified in several forms of malignancy including breast cancer, and is believed to be an etiological factor in carcinogenesis [6] [7] [8] . We, and others, have recently reported that zinc ionophores, such as clioquinol, are likely a new group of anticancer agents targeting both breast and ovarian cancer cells [9] [10] [11] . Zinc at cytotoxic concentrations is targeted to lysosomes whereby it may induce apoptosis in breast cancer cells [12] . Furthermore, at cytotoxic concentrations, zinc also modulates post-transcriptional regulation of gene expression involving the microR-NA processing machinery [13] . However, the effect of zinc at sub-cytotoxic concentrations on HO-1 expression in breast and ovarian cancer cells has not been investigated.
The present study has examined the effects of zinc on HO-1 expression in human breast and ovarian cancer cell model systems. We found that zinc induces HO-1 expression and that this induction is mediated through the Nrf2 signaling pathway.
Materials and Methods

Materials
The pGL3/4.5-HO-1 luciferase reporter construct containing the 4.5 kilobase fragment of the human HO-1 gene promoter was kindly provided by Dr. Anupam Agarwal (University of Alabama at Birmingham, Birmingham, AL). The HO-1 3'-UTR and the glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) 3'-UTR reporter constructs were purchased from SwitchGear Genomics (Menlo Park, CA). The Dual-Luciferase Reporter kit was from Promega (Madison, WI). The QuikChange Site-Directed Mutagenesis Kit was from Stratagene (La Jolla, CA). The Chromatin Immunoprecipitation (ChIP) Assay Kit was from Millipore (Temecula, CA). ZnCl 2 , N-Acetyl-L-cycteine (NAC), N,N,N',N'-Tetrakis (2-pyridylmethyl) ethylenediamine(TPEN), ammonium tetrathiomolybdate (TM), clioquinol, and other chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture
The human ovarian cancer cell line (A2780) was generously provided by Dr. Stephen Howell (University of California, San Diego), and maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics. The human metastatic breast adenocarcinoma cell line (MDA-MB-231) was obtained from the American Type Culture Collection. The human umbilical vein cell line (EA.hy926) was a kind gift from Dr. Doris M. Benbrook (University of Oklahoma Health Sciences Center, Oklahoma City). Both MDA-MB-231 and EA.hy926 cells were grown in DMEM with supplements same as that in RPMI 1640 medium. Cells were cultured in a humidified environment containing 5% CO 2 at 37°C, and passaged twice a week.
Western blot analysis
Western blot was performed as we previously described [9, 14] . Briefly, for cellular protein isolation, cells were lysed with lysis buffer containing 50 mM Tris, pH 7.4, 50 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride (PMSF), 25 µg/ml leupeptin, and 25 µg/ml aprotinin, sonicated on ice for 6 strokes of 10 seconds each, and centrifuged at 15,000×g for 15 minutes to remove insoluble material. For nuclear protein extraction, cells were detached by adding 2.5 ml wash buffer (for a 100-mm 
Luciferase reporter activity assay
Approximately 3×10 6 A2780 cells were seeded in 100-mm cell culture dishes. After 24 hours of plating, cells were transfected with the pGL3/4.5-HO-1, the HO-1 3'-UTR, or the GAPDH 3'-UTR reporter constructs using the Fugene HD transfection reagent (Promega, Madison, WI) as previously described [14, 15] . The next day, cells were lifted and seeded into a 24-well plate at 2×10 5 per well. 48 hours after transfection, cells were treated with various reagents for indicated durations and concentrations. Cell lysates were prepared and luciferase activity was assayed using the Dual-Luciferase Reporter kit (Promega, Madison, WI) as described [14, 15] . The firefly luciferase activity was normalized to the amount of protein used for luciferase activity assay for each sample. The data are expressed as percentages of luciferase activity detected in untreated control cells.
siRNA knockdown of Nrf2 and PPARα siRNA for Nrf2 and PPARα were purchased from Santa Cruz Biotechnology (Dallas, TX). Scrambled non-specific siRNAs were applied as controls. 100 nM (final concentration) siRNAs and 1 μg of PGL3/4.5-HO-1 were co-transfected into A2780 cells cultured in a 60-mm dish following the manufacturer's protocols. On the next day, cells were lifted and plated into 24-well plates (for luciferase activity assay) or 100-mm dishes (for Western blot analysis). 48 hours after the transfection, ZnCl 2 was added to the medium at indicated concentrations for 8 hours. The cells were then lysated and assayed for luciferase activity. The knockdown of Nrf2 and PPARα was confirmed by Western blot analysis.
Generation of PGL3/4.5-HO-1 mutants
The PGL3/4.5-HO-1 construct was served as a parental plasmid to generate mutants with the deletion of the two antioxidant response elements (AREs) [16, 17] and two peroxisome proliferator response element (PPREs) located within the promoter [18] . This was achieved by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The primers used for mutations were as follows: ARE1 deletion (forward), 5'-CGTGCAGCTGCATTTCTTGTTTGGGAGGG-3'; ARE1 deletion (reverse): 5'-CCC-TCCCAAACAAGAAATGCAGCTGCACG-3'; ARE2 deletion (forward): 5'-CGGATTTTGCTAGATTTCCAGTGCCTC-CTCAGC-3'; ARE2 deletion (reverse): 5'-GCTGAGGAGGCACTGGAAAGAGAGCAAAATCCG -3'; PPRE1 deletion (forward): 5'-CTGCCTAGGATGTGCGGCTCCACC-3'; PPRE1 deletion (reverse): 5'-GGTGGAGCCGCACATCC-TAGGCAG-3'; PPRE2 deletion (forward): 5'-CCTTCCCTTAAAGTCCAGGGCCATTCC-3'; PPRE2 deletion (reverse): 5'-GGAATGGCCCTGGACTTTAAGGGAAGG-3'. Single mutations were achieved first, and followed by Double mutations. The mutants were confirmed by direct DNA sequencing.
Chromatin Immunoprecipitation Assay
The ChIP assay was performed with a kit from Millipore (Billerica, MA) as we previously described [19] . In short, A2780 cells were treated with 100 μM ZnCl 2 for 2 hours. Formaldehyde was then added directly to the medium (final concentration, 1%) to cross-link the DNA and transcription factors at 37°C for 10 minutes. Cells were washed, removed from the dish, pelleted, and lysed on ice in the SDS buffer. The lysate was sonicated to shear the DNA into sizes ranging from 200 to 1000 bp and the DNA was pre-cleared for 1 hour on ice with Protein A agarose/salmon sperm DNA (50% slurry). The complex of protein and DNA was precipitated overnight at 4°C using Nrf2, or PPARα antibody, and the complex was then incubated with Protein A agarose/salmon sperm DNA (50% Slurry) for 2 hours at 4°C, washed and eluted. The precipitants were then incubated with NaCl at 65°C for 4 hours to reverse DNA cross-links. The precipitants were then digested with protein kinase K, and DNA was extracted with phenol/chloroform and precipitated with etha- 
Statistical Analysis
All statistical analysis was performed with Graphpad Prism software (San Diego, CA). One-way ANOVA with Dunnett's post-test was used to determine differences among control and experimental groups, with p < 0.05 , p < 0.01, or p < 0.001 as the levels of statistical significance. Cell lysates were prepared, and luciferase activity was assayed. Images are representative of three experiments. Data for luciferase activity are expressed as percentage of the value detected in untreated control cells (bars, SE; n=3). *, P < 0.05, ***, P < 0.001 using one-way ANOVA followed by Dunnett's analysis.
Results
We have previously demonstrated that ZnCl 2 at 50-100 µM is not cytotoxic to human cancer cells [9, 20, 21] . To investigate whether zinc at these concentrations affects HO-1 gene expression, the human ovarian cancer cell line (A2780), the breast cancer cell line (MDA-MB-231), and the non-cancerous umbilical vein endothelial cell line (EA.hy926) were treated with ZnCl 2 at the indicated concentrations and durations. Western blot was performed to analyze HO-1 protein expression. As shown in Figure 1A , the basal level of HO-1 protein expression is barely detectable in all cell lines examined, consistent with our recent report [22] . However, treatment with ZnCl 2 significantly induced HO-1 expression (Fig. 1A) , with initial detection at 6 hours of treatment and maximal induction at 8 hours in A2780 cells (Fig.  1C) . The induction of HO-1 expression by ZnCl 2 was also concentration-dependent (Fig. 1B) .
To determine whether the induction of HO-1 expression by ZnCl 2 is mediated at the transcriptional or post-transcriptional level, the PGL3/4.5-HO-1 promoter reporter construct or the HO-1-3'-UTR reporter construct was transfected into A2780 cells, and the cells . CQ enhances ZnCl 2 -induced HO-1 promoter activity. Cells were transfected with the PGL3/4.5-HO-1 promoter reporter construct and treated with 50 μM or 100 μM ZnCl 2 for 4 hours in the presence or absence of 5 μM CQ after 48 hours of transfection. Cell lysates were prepared, and luciferase activity was assayed. (E). TPEN and NAC, but not TM (a copper chelator) reverse ZnCl 2 -induced HO-1 promoter activity. Cells were transfected with the PGL3/4.5-HO-1 promoter reporter construct and treated with 100 μM ZnCl 2 for 8 hours in the presence or absence of 5 μM TPEN, 5 mM NAC, or 20 μM TM after 48 hours of transfection. Cell lysates were prepared, and luciferase activity was assayed. Data are expressed as percentage of the value detected in untreated control cells (bars, SE; n=3). **, P < 0.01, ***, P<0.001, compared with treated control cells, using one-way ANOVA followed by Dunnett's analysis.
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were treated with 50-200 μM ZnCl 2 for 1-16 hours. The luciferase reporter activity assay indicated that HO-1 promoter activity is significantly induced by ZnCl 2 in a concentration-and time-dependent manner (Fig. 1D, E) , whereas the HO-1-3'-UTR-and GAPDH-3'-UTR-mediated luciferase activity remains unchanged after the treatment (Fig. 1F) . These results clearly indicate that the observed ZnCl 2 -induced increase in HO-1 expression is mediated at the transcriptional level, with peak induction of HO-1 promoter activity at 8 hours of treatment and declined thereafter. Cell lysates were prepared, and luciferase activity was assayed. Data are expressed as percentage of the value detected in untreated control cells (bars, SE; n=3). *, P < 0.05 **, P < 0.01, ***, P < 0.001, compared with untreated control cells, using one-way ANOVA followed by Dunnett's analysis. Forty-eight hours after transfection cells were treated with 100 μM ZnCl 2 for 8 hours. Cell lysates were prepared, and luciferase activity was assayed. Data are expressed as percentages of the value detected in untreated control cells (bar, SE, n=3).
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To understand whether the ZnCl 2 -induced HO-1 expression is due to an increase in intracellular zinc, A2780 cells were treated with ZnCl 2 in the presence or absence of clioquinol (CQ), a well-established zinc ionophore [12] . Addition of CQ (5 µM) significantly enhanced zinc-induced HO-1 gene expression and promoter activity ( Fig. 2A, D) , supporting the idea that increased intracellular zinc accounts for the induction of HO-1. Furthermore, when A2780 cells were pretreated with TPEN, a well-known high-affinity zinc chelator [23] , ZnCl 2 -induced HO-1 expression was abolished (Fig. 2B, E) , further indicating that the increase in intracellular zinc is responsible for HO-1 induction. On the other hand, TM, a well-established copper chelator [24] , had no effect on ZnCl 2 -induced HO-1 promoter activity (Fig. 2E) . Interestingly, NAC, a broadly used antioxidant, blocked ZnCl 2 -induced HO-1 expression and promoter activity (Fig. 2C, E) , suggesting a possibility that ZnCl 2 may induce a transient elevation of oxidative stress in this model system. Elevation of intracellular free zinc levels has been shown to induce oxidative stress in mammalian cells [25] . Because we have recently reported that NAC may interact with copper to generate hydrogen peroxides thus turning an antioxidant into a pro-oxidant [26] , we tested the effect of the combination of NAC and copper on HO-1 expression in A2780 cells. As expected, NAC plus CuCl 2 induced HO-1 expression and promoter activity in this model system (Fig. 3A-C) .
HO-1 gene transcription is typically regulated by the Nrf2 signaling pathway [27] . To determine whether Nrf2 mediates ZnCl 2 -induced HO-1 expression in our model system, a sequence specific siRNA was applied to knockdown Nrf2 expression in A2780 cells (Fig. 4A) . Knockdown of Nrf2 dramatically attenuated the ZnCl 2 -induced increase of HO-1 promoter activity (Fig. 4B) , whereas no significant change was observed after knockdown of PPARα ( Fig. 4A and B) , another transcription factor known to regulate HO-1 expression [18] . These Cell lysates were prepared and luciferase activity was assayed. Data are expressed as percentages of the value detected in untreated control cells (bar, SE, n=3). *, P < 0.05, using one-way ANOVA followed by Dunnett's analysis.
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results support the conclusion that the Nrf2 signaling pathway mediates ZnCl 2 -induced enhancement of HO-1 gene transcription. Western blot analysis confirmed that treatment with ZnCl 2 increases Nrf2 protein expression at both cytoplasmic and nuclear levels in a concentration- (Fig. 5A ) and time-dependent (Fig. 5B) manner.
In the typical scenario, upon activation, Nrf2 will translocate into the nucleus, bind to the AREs and activate HO-1 gene transcription [27] . There are two adjacent AREs identified in the human HO-1 gene promoter (Fig. 6A) [28] . In an attempt to identify the DNA binding elements that mediate ZnCl 2 -induced HO-1 gene transcription, we deleted the two ARE elements from the HO-1 gene promoter construct (pGL3/4.5-HO-1). The two PPRE elements identified in this promoter were also deleted. As shown in Fig. 6B , single deletion of ARE1 (the distal ARE) significantly compromised the ZnCl 2 -induced increase in HO-1 promoter activity. Deletion of both ARE elements completely reversed the ZnCl 2 -induced increase in HO-1 promoter activity. In contrast, deletion of both PPRE elements did not significantly alter ZnCl 2 -induced increase in HO-1 promoter activity (Fig. 6B) . These results indicate that the AREs primarily mediate this event. ChIP analysis was applied to examine the DNA binding activity of Nrf2 in cells that had been treated with ZnCl 2 . The PPARα binding to PPRE was also analyzed as a control. These results show that Nrf2 binding to ARE1 was significantly enhanced while PPARα binding to the PPRE remained unchanged by ZnCl 2 treatment (Fig. 7) .
Discussion
While zinc is known to be involved in the carcinogenesis of various types of cancer [6] [7] [8] , the interaction of zinc with cellular antioxidant enzymes in breast and ovarian cancer cells has never been previously examined. We demonstrated in this study that zinc at sub-cytotoxic concentrations induces HO-1 gene transcription through the Nrf2 signaling pathway in human breast and ovarian cancer cell model systems. As zinc is considered an anticancer agent against various types of malignancy [10] and HO-1 has been shown to induce chemo-resistance of cancer cells [2] [3] [4] , these findings implicate a new angle in understanding zinc's anticancer activity. Specifically, zinc at sub-cytotoxic concentrations may have a preventive effect against carcinogenesis because of the up-regulation of HO-1 expression in normal cells, while it may compromise the effectiveness of chemotherapy as it induces HO-1 expression in cancer cells.
Induction of HO-1 in breast and ovarian cancer cells by zinc has not been previously investigated. The present study showed that treatment with zinc induces HO-1 expression in both breast and ovarian cancer model systems. The induction clearly takes place at the transcription level, as both protein expression and the HO-1 promoter-driven reporter activity are up-regulated by zinc. Furthermore it was demonstrated that it is not extracellular zinc ions that induce HO-1 expression, rather it is the increase in intracellular zinc that enhances HO-1 gene transcription; as evidenced by the addition of a zinc chelator to reverse the induction, and a zinc ionophore to further enhance the induction. It is interesting to note that HO-1 induction is also relatively transient, being detected at 4 hours after zinc treatment and at maximum induction at 8 hours, and declined thereafter, which is reminiscent of HO-1 induction seen in different experimental model systems [29] [30] [31] . As a consequence of HO-1 induction, cancer cells may develop chemo-resistance [2] , implying that zinc at sub-cytotoxic concentrations may increase chemo-resistance of cancer cells. On the other hand, previous reports have also indicated that supplementation with zinc may restore p53 function and suppress HIF-1α activity, thereby sensitizing cancer cells to chemotherapy in vivo [32, 33] . Thus, the biological consequences of zinc-induced HO-1 expression in cancer cells merit further investigation.
Zinc is known to regulate gene transcription in many model systems [34] . We have previously reported that NF-kappa B and PPARα signaling are involved in zinc ionophore-induced anticancer activity [9, 35] and that zinc at cytotoxic concentrations could alter post-transcriptional events of gene expression in cancer cells [13] . In the present study, we have obtained strong evidence indicating that zinc-induced HO-1 expression is mediated through transcriptional regulation via the Nrf2 signaling pathway. First, we knocked down Nrf2 or PPARα expression and observed that only Nrf2 knockdown attenuated the ZnCl 2 -induced HO-1 gene transcription; indicating that the Nrf2 signaling pathway, but not the PPARα pathway, is involved in this event. Second, deletion of the AREs from the HO-1 gene promoter abolished ZnCl 2 -induced HO-1 gene promoter activity, while deletion of the PPREs had no significant effect on the induction. The ARE is an established DNA cis-element bound by Nrf2 [1] . Third, nuclear Nrf2 levels and Nrf2 binding to the ARE1 in the HO-1 gene promoter was significantly increased by zinc treatment, confirming that zinc activates the Nrf2 signaling pathway leading to enhanced HO-1 gene expression. Finally, when NAC, an antioxidant was applied, the zinc-induced HO-1 expression was attenuated, suggesting that a certain level of oxidative stress is involved in HO-1 induction, which is consistent with the fact that up-regulation of the Nrf2 pathway is often associated with increased oxidative stress [1] . While zinc is generally considered an antioxidant, high levels of free intracellular zinc ion have been described to facilitate oxidative stress in mammalian cell model system [25] .
In summary, we have demonstrated that zinc at sub-cytotoxic concentrations transiently induces HO-1 expression in breast and ovarian cancer model systems, which is mediated through the Nrf2 signaling pathway. These findings implicate that the effective application of zinc as an anticancer agent, whether for prevention or therapy, may depend on the concentrations used, a concept worth further exploration.
